Cost-effectiveness analysis assesses survival and healthcare costs in patients with transfusion-dependent β-thalassemia, indicating potential benefits of exagamglogene treatment.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Udeze et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: